These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17695482)

  • 41. Nonmyeloablative transplantation: an allogeneic-based immunotherapy for renal cell carcinoma.
    Takahashi Y; Childs RW
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6353S-9S. PubMed ID: 15448030
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy.
    Fumagalli L; Lissoni P; Di Felice G; Meregalli S; Valsuani G; Mengo S; Rovelli F
    Br J Cancer; 1999 May; 80(3-4):407-11. PubMed ID: 10408846
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients.
    Bordin V; Giani L; Meregalli S; Bukovec R; Vaghi MM; Mandalà M; Paolorossi F; Ardizzoia A; Tancini G; Barni S; Frigerio F; Fumagalli L; Bordoni A; Valsuani G; Di Felice G; Lissoni P
    Urol Int; 2000; 64(1):3-8. PubMed ID: 10782024
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The association between social support, intrusive thoughts, avoidance, and adjustment following an experimental cancer treatment.
    Devine D; Parker PA; Fouladi RT; Cohen L
    Psychooncology; 2003; 12(5):453-62. PubMed ID: 12833558
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low-dose recombinant IL-2 induces psychological changes: monitoring by Minnesota Multiphasic Personality Inventory (MMPI).
    Pizzi C; Caraglia M; Cianciulli M; Fabbrocini A; Libroia A; Matano E; Contegiacomo A; Del Prete S; Abbruzzese A; Martignetti A; Tagliaferri P; Bianco AR
    Anticancer Res; 2002; 22(2A):727-32. PubMed ID: 12014643
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Preoperative subcutaneous immunotherapy with interleukin-2 in renal carcinoma with synchronous metastasis: randomized clinico-biological study. Preoperative use of Il-2 in renal carcinoma].
    Scardino E; Lissoni P; Andres M; Frea B; Favini P; Kocjancic E; Verweij F; Barani S; Tancini G; Rocco F
    Arch Ital Urol Androl; 1997 Feb; 69(1):49-54. PubMed ID: 9181906
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Lymphocyte levels before treatment with subcutaneous interleukin-2 and during maintenance treatment in relation to the clinical efficacy in metastatic renal carcinoma].
    Viganò MG; Lissoni P; Barni S; Tancini G; Scardino E; Favini P; Baccalini A; Verweij F; Strada G; Rocco F
    Arch Ital Urol Androl; 1995 Apr; 67(2):143-7. PubMed ID: 7787856
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Normalization of idiopathic arterial hypertension following cancer immunotherapy with interleukin-2.
    Lissoni P; Bastone A; Barni S; Tancini G; Galli MA
    J Biol Regul Homeost Agents; 1994; 8(2):65-6. PubMed ID: 7863816
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Allogeneic gene-modified tumour cells in metastatic kidney cancer. Preliminary report.
    Pizza G; De Vinci C; Lo Conte G; Mazzuca A; Corrado G; Menniti D; Benati A; Romagnoli P; Fornarola V; Busutti L; Palareti A; Capanna R; Di Maio V; Ratini S; Gulino A; Vacca A; Melchiorri L; Ferrari M; Boriani S; Baricordi RO
    Folia Biol (Praha); 2003; 49(4):147-59. PubMed ID: 12971584
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Integrative tumor board: metastatic renal cell carcinoma: psycho-oncology.
    Block PB
    Integr Cancer Ther; 2004 Mar; 3(1):41-4. PubMed ID: 15035874
    [No Abstract]   [Full Text] [Related]  

  • 51. Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival.
    Donskov F; Bennedsgaard KM; Von Der Maase H; Marcussen N; Fisker R; Jensen JJ; Naredi P; Hokland M
    Br J Cancer; 2002 Jul; 87(2):194-201. PubMed ID: 12107842
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Life quality of patients with metastatic renal cell carcinoma and chemo-immunotherapy--a pilot study.
    Kröger MJ; Menzel T; Gschwend JE; Bergmann L
    Anticancer Res; 1999; 19(2C):1553-5. PubMed ID: 10365144
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lymphocytosis decline is not responsible for tumor progression in cancer patients chronically treated with interleukin-2.
    Lissoni P; Barni S; Andres M; Scardino E; Vigoré L; Vezzo R; Rescaldani R; Tancini G
    Tumori; 1994 Aug; 80(4):283-5. PubMed ID: 7974799
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neuro-psychological discorders and renal cell carcinoma: a case report and a psychological study of urological cancer patients.
    Kato M; Miyakawa M; Okada K
    Anticancer Res; 2000; 20(1C):641-3. PubMed ID: 10769709
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?
    Lissoni P; Brivio F; Viviani S; Fumagalli L
    J Biol Regul Homeost Agents; 1999; 13(2):110-4. PubMed ID: 10503734
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin: a biological phase II study.
    Lissoni P; Barni S; Brivio F; Rossini F; Fumagalli L; Tancini G
    J Biol Regul Homeost Agents; 1995; 9(2):52-4. PubMed ID: 9127633
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metastatic renal cell carcinoma: CT-guided immunotherapy as a technically feasible and safe approach to delivery of gene therapy for treatment.
    Suh RD; Goldin JG; Wallace AB; Sheehan RE; Heinze SB; Gitlitz BJ; Figlin RA
    Radiology; 2004 May; 231(2):359-64. PubMed ID: 15128982
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy.
    Fumagalli LA; Vinke J; Hoff W; Ypma E; Brivio F; Nespoli A
    J Immunother; 2003; 26(5):394-402. PubMed ID: 12973028
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunotherapy of metastatic renal cell cancer.
    Fishman M; Seigne J
    Cancer Control; 2002; 9(4):293-304. PubMed ID: 12228755
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The observation on treatment effects of local adoptive immunotherapy in 33 cases with head and neck cancer].
    Han D; Zhu X; Huang Z
    Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):454-6. PubMed ID: 10920882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.